Health & Biotech

Best Biopharma Investments in North America: Why Amgen and Sanofi Are Doubling Down

Wednesday, 6 May 2026 4:32PM UTC

Shoppers of talent and capacity are watching big pharmas double down in North America: Amgen is ploughing another $300m into its Puerto Rico biologics plant while Sanofi is committing $294m to grow an AI centre in Toronto , moves that aim to secure supply chains and speed drug development.

Essential Takeaways

Amgen boost: $300m extra for Puerto Rico expands biologics capacity, modernises tech and supports workforce training.
Sanofi focus: $294m for Toronto funds an AI centre of excellence, adding about 50 specialised roles for data and manufacturing tools.
Jobs and skills: Amgen’s year-long push lifts regional pharma investment above $2bn; Sanofi’s spend increases the number of tech-savvy life‑science positions locally.
Why it matters: The investments strengthen domestic production resilience and inject digital tools into drug manufacturing, improving predictability and supply reliability.

Why Amgen is betting on Puerto Rico’s labs again

Amgen’s fresh $300m commitment follows a larger expansion it announced last year, and it’s as much about politics as production , the White House has been urging reshoring of critical drug manufacturing. The cash will beef up biologics production capacity, introduce next‑generation manufacturing technologies and fund workforce development on the island. Puerto Rico has a long pharmaceutical pedigree and, according to Amgen, this new tranche adds to almost $2bn of investments there in the past year, signalling renewed confidence after decades of industry churn. For companies eyeing supply resilience, the lesson is obvious: proximity and upgraded facilities matter when demand spikes or geopolitics shifts. If you’re tracking manufacturing jobs, expect construction roles first and a slower roll‑out of permanent lab positions.

Sanofi’s Toronto play is about smarter manufacturing, not just headcount

Sanofi’s $294m will enlarge an AI “centre of excellence” opened in 2022, with roughly 50 new hires focused on developing AI tools for manufacturing and supply chain decision‑making. The site already created more than 150 roles over four years, so this is a scaling rather than a start‑up sprint. The French group sees digital simulation, real‑time monitoring and predictive systems as the future of pharma production, which could reduce waste and speed up batch troubleshooting. For life‑sciences regions, the headline is clear: tech talent is now as strategic as factory floors. If you want a job in pharma tech, look at data science, software engineering and applied AI in manufacturing contexts.

What these moves say about a wider industry trend

Between large capital builds and digital centres, the sector is split between hard infrastructure and soft, high‑skill capability. Amgen’s plant expansion adds tangible capacity to produce biologics; Sanofi’s investment adds intangible but crucial digital muscle. Together they embody a twin strategy that other firms are copying: secure where medicines are made while making production smarter. This hybrid approach also mirrors government priorities , regional officials in Puerto Rico and Ontario have both welcomed the investments as job creators and economic stabilisers. For regional economies, these contracts are lifelines that can attract suppliers and training programmes for years.

Practical advice for local workers and policymakers

If you live near these sites, now’s a good time to refresh technical skills or pursue short courses in biotech manufacturing, quality systems or industrial AI tools. Employers will need people who can bridge lab know‑how and data literacy. Policymakers, meanwhile, should keep aligning incentives, training funds and infrastructure upgrades so that promised jobs translate into local hires. For investors or procurement teams, the takeaway is that diversified supply , combining onshore biologics capacity with AI‑driven process reliability , reduces risk. Ask prospective suppliers how they’re using digital twins or predictive maintenance before committing to long‑term contracts.

What to watch next: delivery, jobs and tech transfer

The real test isn’t the headlines but execution: how quickly will factories scale up, how many permanent roles materialise, and how effectively will AI tools move from pilot to plant floor? Amgen’s earlier projection suggested nearly 750 jobs from its previous investment; the firm hasn’t given an immediate job count for this latest outlay. Sanofi’s hiring is more explicit but small in number, reflecting specialised skills rather than mass production roles. Expect updates on construction milestones, recruitment drives and early case studies of AI preventing downtime. These will determine whether the dollar amounts translate into more reliable medicines and smarter manufacturing , and that’s what patients and taxpayers ultimately want.

It's a small change that can make supply chains steadier and manufacturing smarter.

Source Reference Map

Story idea inspired by: ^[1]

Sources by paragraph:

Paragraph 1: ^[2], ^[6]
Paragraph 2: ^[6], ^[4]
Paragraph 3: ^[5], ^[3]
Paragraph 4: ^[6], ^[5]
Paragraph 5: ^[2], ^[3]

More on this

https://www.biospace.com/business/amgen-sanofi-commit-nearly-600m-to-north-american-expansions - Please view link - unable to able to access data
https://www.amgen.com/newsroom/press-releases/2026/05/amgen-announces-additional-300-million-us-manufacturing-investment-totaling-nearly-2-billion-over-the-last-year - Amgen has announced an additional $300 million investment in its U.S. manufacturing network, aiming to enhance production capacity and integrate next-generation technologies. This expansion focuses on the Juncos site in Puerto Rico, established in 1992, which is among the largest biomanufacturing facilities globally, supplying biologic medicines to over 60 countries. The investment is expected to strengthen existing manufacturing roles, support workforce development, and generate hundreds of construction jobs, reinforcing Amgen's commitment to American manufacturing and the resilience of the domestic supply chain.
https://news.ontario.ca/en/release/1007396/ontario-welcomes-294-million-investment-in-the-life-sciences-sector - Sanofi is investing $294 million to expand its Artificial Intelligence Centre of Excellence in Toronto, aiming to create 50 new high-skilled jobs in AI and machine learning. This expansion builds upon over 150 roles established since 2022 and underscores Ontario's position as a global leader in life sciences and AI. The investment will enhance Sanofi's global research, manufacturing, and business operations, accelerating the development of innovative treatments and reinforcing the province's digital workforce.
https://www.pacbiztimes.com/2026/05/04/amgen-invests-300m-into-u-s-manufacturing-capabilites/ - Amgen has announced a $300 million investment to expand its U.S. manufacturing capabilities, focusing on the Juncos site in Puerto Rico. This facility, operational since 1992, produces biologic medicines distributed to more than 60 countries. The expansion aims to strengthen existing manufacturing roles, support workforce development, and generate hundreds of construction jobs, reflecting Amgen's commitment to American manufacturing and the resilience of the domestic supply chain.
https://www.pharmamanufacturing.com/industry-news/news/55375522/sanofi-invests-294m-to-expand-ai-center-of-excellence-in-toronto - Sanofi is investing $294 million to expand its global Artificial Intelligence Center of Excellence in Toronto, Canada. This expansion is expected to create 50 new high-skilled jobs in AI and machine learning by 2028, supporting technology partnerships and the growth of the Center of Excellence facilities. Established in 2022, the Center co-locates data, AI, scientific, manufacturing, and product teams to enable Sanofi's work across the full life sciences value chain, accelerating the development of innovative treatments and vaccines.
https://www.pharmamanufacturing.com/facilities/article/55375383/amgen-adds-300m-investment-to-biologics-manufacturing-facility-in-puerto-rico - Amgen is investing an additional $300 million to expand its biologics manufacturing facility in Juncos, Puerto Rico. This investment aims to advance U.S.-based production capacity and enhance next-generation technologies. The Juncos site is one of the world's largest and most advanced biomanufacturing facilities, producing biologic medicines for more than 60 countries. The expansion is expected to strengthen existing manufacturing roles, support workforce development, and generate hundreds of construction jobs, reinforcing Amgen's commitment to American manufacturing and the resilience of the domestic supply chain.
https://ca.investing.com/news/stock-market-news/amgen-to-invest-300-million-in-puerto-rico-manufacturing-facility-93CH-4606403 - Amgen has announced plans to invest $300 million in its U.S. manufacturing network, specifically expanding its biologics manufacturing facility in Puerto Rico. The investment will expand the company’s Juncos site, which has operated since 1992 and produces biologic medicines distributed to more than 60 countries. The expansion is expected to create hundreds of construction jobs and strengthen existing manufacturing roles in the region, reflecting Amgen's commitment to American manufacturing and the resilience of the domestic supply chain.

Noah Fact Check Pro

The draft above was created using the information available at the time the story first emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed below. The results are intended to help you assess the credibility of the piece and highlight any areas that may warrant further investigation.

Freshness check

Score: 8

Notes: The article reports on recent investments by Amgen and Sanofi, with Amgen's $300 million investment announced on May 4, 2026, and Sanofi's $294 million investment in Toronto. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2026/05/amgen-announces-additional-300-million-us-manufacturing-investment-totaling-nearly-2-billion-over-the-last-year?utm_source=openai)) The article was published on May 6, 2026, indicating timely reporting. However, the article references a previous $650 million investment by Amgen in Puerto Rico, announced in September 2025, which may affect the perceived freshness of the content. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2026/05/amgen-announces-additional-300-million-us-manufacturing-investment-totaling-nearly-2-billion-over-the-last-year?utm_source=openai))

Quotes check

Score: 7

Notes: The article includes direct quotes from Amgen CEO Robert A. Bradway and Puerto Rico Governor Jenniffer González Colón. ([amgen.com](https://www.amgen.com/newsroom/press-releases/2026/05/amgen-announces-additional-300-million-us-manufacturing-investment-totaling-nearly-2-billion-over-the-last-year?utm_source=openai)) A search for these quotes reveals that they have been used in previous publications, suggesting potential reuse of content. The exact earliest known usage of these quotes is not specified, but their repetition across multiple sources raises concerns about originality.

Source reliability

Score: 6

Notes: The article is published on BioSpace, a niche publication focusing on the life sciences industry. While it is reputable within its niche, its reach and influence are limited compared to major news organisations. The article references press releases from Amgen and Sanofi, which are primary sources but may present information with inherent biases. The reliance on press releases and a niche publication for reporting raises concerns about the independence and comprehensiveness of the information.

Plausibility check

Score: 8

Notes: The reported investments by Amgen and Sanofi align with known industry trends of increasing investment in North American manufacturing and AI capabilities. Amgen's previous $650 million investment in Puerto Rico and Sanofi's focus on AI in Toronto are consistent with their strategic priorities. However, the article does not provide detailed information on the specific projects or expected outcomes of these investments, which limits the ability to fully assess the plausibility of the claims.

Overall assessment

Verdict (FAIL, OPEN, PASS): FAIL

Confidence (LOW, MEDIUM, HIGH): MEDIUM

Summary: The article reports on recent investments by Amgen and Sanofi, with timely reporting and references to primary sources. However, the reuse of quotes from previous publications, reliance on press releases, and the use of a niche publication for reporting raise concerns about the originality, independence, and comprehensiveness of the information. The lack of independent verification from third-party sources further diminishes the reliability of the content. Given these issues, the article does not meet the standards for a PASS verdict.